Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Zevra Therapeutics, Inc.

NASDAQ: ZVRA · Life Sciences · 3 alerts · CIK 1434647

Share price
$9.25Close, Nov 16
Market cap
$550M
Shares outstanding
59.5MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Zevra Therapeutics, Inc. filings on SEC EDGAR ↗

5:17 PM ET 10-Q
Financial Results

Zevra Therapeutics Q3 2026 Results: Turns Profitable, Net Income $19.2M

Zevra Therapeutics reported a significant financial turnaround for the nine months ended September 30, 2026, with net income of $65.85 million compared to a net loss of $72.26 million in the prior year period. This improvement was driven by a 57% increase in net revenue and a $43.3 million gain on the sale of future royalties and intellectual property.

Key figure
Net income $19.2M
4:09 PM ET 8-K
Financial Results

Zevra Therapeutics Financial Results

Zevra Therapeutics reported Q3 2026 net revenue of $37.8 million, a 45% increase year-over-year, primarily driven by $34.0 million in sales from MIPLYFFA. The company achieved net income of $19.2 million for the quarter and maintained a strong cash position of $270.9 million to support its rare disease pipeline.

Term
Q3 2026

“In the third quarter, we made continued progress across our business, building on MIPLYFFA's commercial performance in the U.S. and advancing our pipeline in support of our mission to redefine what’s possible in bringing life-changing therapies to people living with rare disease.”

Neil F. McFarlane, Zevra's President and Chief Executive Officer

“We remain focused on reaching more people living with Niemann-Pick disease type C, advancing celiprolol for vascular Ehlers-Danlos syndrome, and pursuing European access to arimoclomol. Our strong financial position enables us to advance these priorities while continuing to make arimoclomol available to eligible patients through our global Expanded Access Program.”

Neil F. McFarlane, Zevra's President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.